Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-217A/Alendronate 70-mg/Vitamin D3 Combination · 1 trial · 1 indication
Serum samples to measure serum 25-hydroxyvitamin D \[25(OH)D\] will be collected at specific visits during the treatment phase of the study.
| Arm | Type | Description |
|---|---|---|
| Fosamax Plus | EXPERIMENTAL | Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants |
| Name | Type | Description |
|---|---|---|
| MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet | DRUG | One combination tablet orally once a week |
Inclusion Criteria: * Man aged 50 or older, or a woman who is postmenopausal on day of signing informed consent or has been menopausal for at least one year * Meets bone mineral density (BMD) criteria * Agree to discontinue any osteoporosis drug treatment for duration of study Exclusion Criteria: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |